The efficacy of probiotics in IBS. J Clin Gastroenterol

Typeset version

 

TY  - JOUR
AU  - Quigley, E. M.
PY  - 2008
C2  - July
TI  - The efficacy of probiotics in IBS. J Clin Gastroenterol
AV  - Validated
C1  - Not Avail. ()
NV  - 42 Suppl 2
EP  - 90
AB  - The clear delineation of a postinfective variety of irritable bowel syndrome (IBS), and the description, in a number of studies, of evidence of low-grade inflammation and immune activation in IBS, suggest a role for a dysfunctional relationship between the indigenous flora and the host in IBS and, accordingly, provide a clear rationale for the use of probiotics in this disorder. Other modes of action, including bacterial displacement and alterations in luminal contents, are also plausible. Although clinical evidence of efficacy is now beginning to emerge, a review of available trials emphasizes the importance of clear definition of strain selection, dose, and viability. The possible roles of cotherapy or sequential therapy with antibiotics, probiotics, prokinetics, or other agents, also deserve further study. The role of the enteric flora is evidently an area of great potential in IBS; we are on the threshold of a new era of research and therapy for this common disorder.
SN  - 1539-2031 (Electronic) 01
UR  - http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve;db=PubMed;dopt=Citation;list_uids=18542036
DA  - 2008/07
ER  - 
@article{V18608437,
  author = {Quigley,  E. M. },
  year = {2008},
  month = {July},
  TITLE = {{The efficacy of probiotics in IBS. J Clin Gastroenterol}},
  status = {Validated},
  note = {Citations: {Not Avail. ()}},
  volume = {42 Suppl 2},
  ABSTRACT = {{The clear delineation of a postinfective variety of irritable bowel syndrome (IBS), and the description, in a number of studies, of evidence of low-grade inflammation and immune activation in IBS, suggest a role for a dysfunctional relationship between the indigenous flora and the host in IBS and, accordingly, provide a clear rationale for the use of probiotics in this disorder. Other modes of action, including bacterial displacement and alterations in luminal contents, are also plausible. Although clinical evidence of efficacy is now beginning to emerge, a review of available trials emphasizes the importance of clear definition of strain selection, dose, and viability. The possible roles of cotherapy or sequential therapy with antibiotics, probiotics, prokinetics, or other agents, also deserve further study. The role of the enteric flora is evidently an area of great potential in IBS; we are on the threshold of a new era of research and therapy for this common disorder.}},
  issn = {1539-2031 (Electronic) 01},
  url = {http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve;db=PubMed;dopt=Citation;list_uids=18542036},
  source = {IRIS}
}
AUTHORSAUauthorQuigley, E. M.
YEARPYyear2008
MONTHC2monthJuly
JOURNAL_CODET2journal
TITLETItitleThe efficacy of probiotics in IBS. J Clin Gastroenterol
STATUSAVstatusValidated
TIMES_CITEDC1citationsNot Avail. ()
SEARCH_KEYWORDKWkeywords
VOLUMENVvolume42 Suppl 2
ISSUEISnumber
START_PAGESPpages
END_PAGEEPpages90
ABSTRACTABabstractThe clear delineation of a postinfective variety of irritable bowel syndrome (IBS), and the description, in a number of studies, of evidence of low-grade inflammation and immune activation in IBS, suggest a role for a dysfunctional relationship between the indigenous flora and the host in IBS and, accordingly, provide a clear rationale for the use of probiotics in this disorder. Other modes of action, including bacterial displacement and alterations in luminal contents, are also plausible. Although clinical evidence of efficacy is now beginning to emerge, a review of available trials emphasizes the importance of clear definition of strain selection, dose, and viability. The possible roles of cotherapy or sequential therapy with antibiotics, probiotics, prokinetics, or other agents, also deserve further study. The role of the enteric flora is evidently an area of great potential in IBS; we are on the threshold of a new era of research and therapy for this common disorder.
PUBLISHER_LOCATIONCYaddress
ISBN_ISSNSNisbn1539-2031 (Electronic) 01
EDITIONETedition
URLURurlhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve;db=PubMed;dopt=Citation;list_uids=18542036
DOI_LINKL3doi
FUNDING_BODYM2note
GRANT_DETAILSM2note